Nivolumab (Opdivo) is a fully human IgG4 monoclonal antibody that targets the programmed cell death-1 (PD-1) immune checkpoint receptor on T lymphocytessynapse.patsnap.comsynapse.patsnap.com. By blocking PD-1, nivolumab “releases the brakes” on the immune system, enabling T cells to mount a stronger anti-tumor responsesynapse.patsnap.com. Since its initial approval in 2014, nivolumab has become a cornerstone of cancer immunotherapy, with broad regulatory approvals across many tumor types. This article provides a detailed overview of nivolumab’s mechanism of action, approved oncology indications (with disease stage and line of therapy), key clinical trial results (notably the CheckMate trial program), comparative effectiveness versus other treatments, safety profile including immune-related adverse events, and considerations of cost and access.

Mechanism of Action

Nivolumab is an immune checkpoint inhibitor that specifically targets the PD-1 pathway. PD-1 is an inhibitory receptor expressed on activated T cells (as well as B cells and NK cells) that normally helps maintain self-tolerance by dampening T-cell activity when engaged by its ligands PD-L1 or PD-L2synapse.patsnap.comsynapse.patsnap.com. Tumor cells often exploit this pathway by expressing PD-L1, thereby sending a “stop” signal to T cells and evading immune attacksynapse.patsnap.comsynapse.patsnap.com. Nivolumab binds with high affinity to the PD-1 receptor on T cells and blocks it from interacting with PD-L1/PD-L2 on tumor or antigen-presenting cellssynapse.patsnap.comsynapse.patsnap.com. This blockade lifts the inhibitory signal and reactivates cytotoxic T lymphocytes in the tumor microenvironmentsynapse.patsnap.com. In essence, nivolumab restores T-cell proliferation and function, leading to renewed immune-mediated tumor cell killingsynapse.patsnap.com. Importantly, because nivolumab targets PD-1 (rather than PD-L1), it prevents signaling from both PD-L1 and PD-L2 ligands, potentially yielding a broad enhancement of anti-tumor immunitypmc.ncbi.nlm.nih.govsynapse.patsnap.com. The clinical effect is an increase in tumor-infiltrating T cell activity and, in a subset of patients, durable tumor regression. Nivolumab is used both as monotherapy and in combination with other therapies (e.g. the CTLA-4 inhibitor ipilimumab) to amplify anti-cancer immune responsessynapse.patsnap.com.

Approved Indications

Since its introduction, nivolumab has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for numerous cancers. Key FDA/EMA-approved indications (with disease setting and line of therapy) include the followingdrugs.compahealthwellness.com:

• Melanoma: Unresectable or metastatic melanoma (adult and pediatric ≥12 years) as first-line therapy or beyond, either as monotherapy or in combination with ipilimumabpahealthwellness.com. Nivolumab is also approved as adjuvant treatment after complete resection of melanoma (Stage IIB, IIC, III, or IV) to reduce recurrence riskpahealthwellness.com.
• Non–Small Cell Lung Cancer (NSCLC): Multiple indications across stages. In resectable NSCLC (tumors ≥4 cm or node-positive), nivolumab with platinum-based chemotherapy is approved as neoadjuvant treatment prior to surgerypahealthwellness.com. For metastatic NSCLC, nivolumab has approval as second-line therapy after platinum-based chemotherapy (regardless of PD-L1 status, based on improved survival vs docetaxel)pahealthwellness.com. Additionally, in first-line metastatic NSCLC without EGFR/ALK mutations, nivolumab can be used in combination regimens: (1) nivolumab + ipilimumab for tumors with PD-L1 ≥1%pahealthwellness.com, or (2) nivolumab + ipilimumab + 2 cycles of chemotherapy for all PD-L1 levelspahealthwellness.com (these reflect CheckMate-227 and CheckMate-9LA regimen approvals).
• Malignant Pleural Mesothelioma: First-line treatment of unresectable pleural mesothelioma in adults, in combination with ipilimumabpahealthwellness.com. This dual immunotherapy regimen was the first to show a survival benefit over chemotherapy in mesothelioma.
• Renal Cell Carcinoma (RCC): Approved in advanced or metastatic RCC. Nivolumab monotherapy is indicated for patients who have received prior anti-angiogenic therapy (second-line)pahealthwellness.com, based on improved survival vs everolimus. In previously untreated advanced RCC, nivolumab is approved in combination with ipilimumab for intermediate or poor-risk patients (first-line), and in combination with cabozantinib (a tyrosine kinase inhibitor) for all risk groups (first-line)pahealthwellness.com.
• Classical Hodgkin Lymphoma (cHL): Adult patients with relapsed or refractory cHL after autologous stem-cell transplantation (HSCT) and brentuximab vedotin, or after ≥3 lines of systemic therapy (if transplant not an option)pahealthwellness.com. This accelerated approval was based on high response rates in heavily pretreated Hodgkin’s lymphoma.
• Head and Neck Squamous Cell Carcinoma (HNSCC): Recurrent or metastatic HNSCC in adults with disease progression on or after platinum-based chemotherapypahealthwellness.com. Nivolumab in this second-line setting was the first immunotherapy to demonstrate an overall survival benefit in head and neck cancerdrugs.com.
• Urothelial Carcinoma (Bladder Cancer): Indicated in two settings: (1) as adjuvant therapy after surgical resection of high-risk muscle-invasive urothelial carcinomapahealthwellness.com, and (2) for locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-based chemotherapy (or within 12 months of neoadjuvant/adjuvant platinum)pahealthwellness.com. (Nivolumab was approved in this second-line setting via accelerated approval on response rate datanews.bms.com.)
• Colorectal Cancer (CRC): Microsatellite instability-high or mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer. Initially approved for patients who have progressed after standard chemotherapy (fluoropyrimidine, oxaliplatin, and irinotecan), as monotherapy or with ipilimumabpahealthwellness.com. More recently, the FDA expanded approval to first-line treatment of MSI-H/dMMR metastatic CRC in combination with ipilimumabdrugs.com, based on a phase 3 trial showing superior outcomes vs chemotherapy.
• Hepatocellular Carcinoma (HCC): Nivolumab (often with ipilimumab) is approved in advanced HCC. It received accelerated approval for patients who had progressed on sorafenib (second-line), although the single-agent post-sorafenib indication was later withdrawn after confirmatory trial resultsdrugs.comdrugs.com. In 2025, nivolumab + ipilimumab gained approval as a first-line treatment for unresectable or metastatic HCC, after demonstrating improved overall survival vs tyrosine kinase inhibitors in a phase 3 trial (CheckMate-9DW)drugs.comdrugs.com.
• Esophageal and Gastroesophageal Cancers: Multiple indications in esophageal cancer: (1) Adjuvant nivolumab for adults with completely resected esophageal or gastroesophageal junction (GEJ) cancer who had residual disease after neoadjuvant chemoradiation (to improve disease-free survival)pahealthwellness.com. (2) First-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC): either nivolumab plus chemotherapy, or nivolumab plus ipilimumab, both of which showed superior survival vs chemotherapy alone (CheckMate-648)pahealthwellness.com. (3) Second-line treatment of advanced ESCC after prior fluoropyrimidine/platinum chemotherapy: nivolumab monotherapy improved overall survival in this setting (based on the ATTRACTION-3 trial)fda.gov. Furthermore, nivolumab + chemotherapy is approved in first-line therapy for advanced or metastatic gastric cancer, GEJ cancer, or esophageal adenocarcinoma (regardless of PD-L1 status)pahealthwellness.com. This approval was driven by the CheckMate-649 trial, where adding nivolumab to chemotherapy significantly improved survival in HER2-negative gastric/GEJ cancersdrugs.compubmed.ncbi.nlm.nih.gov.
• Malignant Pleural Mesothelioma: As noted above, first-line treatment of unresectable pleural mesothelioma in adults, in combination with ipilimumabpahealthwellness.com, based on a survival benefit over standard chemotherapy (CheckMate-743).

(Note: Nivolumab previously had an accelerated approval in third-line small-cell lung cancer, but this indication was voluntarily withdrawn after failure to confirm benefitdrugs.com. As of 2025, the above list represents the major approved uses of nivolumab in the U.S. and EU.)

Clinical Trial Data

Melanoma (Advanced and Adjuvant): Nivolumab has demonstrated landmark efficacy in advanced melanoma. In the CheckMate-066 trial (Phase 3, first-line metastatic melanoma), nivolumab significantly improved overall survival compared to chemotherapy, establishing PD-1 blockade as superior to dacarbazine in untreated patientssynapse.patsnap.comsynapse.patsnap.com. The CheckMate-067 trial further compared nivolumab, ipilimumab, and the combination in untreated metastatic melanoma. Five-year follow-up showed 52% of patients alive at 5 years with nivolumab+ipilimumab, 44% with nivolumab alone, versus 26% with ipilimumab alonenejm.org. Nivolumab (alone or with ipilimumab) not only prolonged progression-free survival (PFS) and overall survival (OS) versus ipilimumabnejm.orgpmc.ncbi.nlm.nih.gov, but also produced higher objective response rates (ORR). These durable responses led to long-term survival plateaus in a substantial subset of patients. In resected high-risk melanoma, CheckMate-238 compared adjuvant nivolumab to high-dose ipilimumab. Nivolumab significantly improved recurrence-free survival with a more favorable safety profile, making it the preferred adjuvant therapy in stage III/IV melanomapmc.ncbi.nlm.nih.gov. Similarly, the recent CheckMate-76K trial in stage IIB/IIC melanoma (whose results underpinned approval in those stages) showed that 12 months of adjuvant nivolumab reduced the risk of recurrence compared to placebodrugs.com. Overall, across melanoma trials, nivolumab has consistently demonstrated high response rates and extended survival, establishing PD-1 blockade as a standard of care in both metastatic and adjuvant settingsnejm.org.

Non–Small Cell Lung Cancer: Nivolumab was initially tested in refractory NSCLC and became the first PD-1 inhibitor to improve survival in this disease. CheckMate-017 (squamous NSCLC) and CheckMate-057 (non-squamous NSCLC) were pivotal phase 3 trials in patients with advanced NSCLC who had progressed after platinum chemotherapy. Nivolumab monotherapy significantly prolonged OS in both trials compared to docetaxel chemotherapynews.bms.com. In squamous NSCLC, median OS improved to around 9–10 months with nivolumab vs ~6 months with chemotherapy (HR ~0.59–0.62)news.bms.com. In non-squamous NSCLC, median OS was ~12.2 months with nivolumab vs 9.4 months with chemotherapy (HR ~0.73)news.bms.com. Notably, 2- and 3-year survival rates roughly doubled with nivolumab in these trials; for example, at 3 years, 16% of squamous NSCLC patients on nivolumab were alive vs 6% on docetaxelnews.bms.com. These durable benefits were observed even in some tumors with low PD-L1 expression, though higher PD-L1 levels correlated with greater benefit in non-squamous histologynews.bms.com. Building on second-line success, nivolumab has been studied in the first-line setting. CheckMate-227 (Part 1) evaluated nivolumab-based combinations in treatment-naïve metastatic NSCLC. In patients with PD-L1 ≥1%, nivolumab + ipilimumab significantly improved OS versus platinum-doublet chemotherapy (median OS 17.1 vs 14.9 months, HR 0.79)drugs.com. Notably, in PD-L1 <1% tumors, the combination also showed benefit when using high tumor mutational burden as a selection criterion. Another trial, CheckMate-9LA, tested a limited-course chemo plus nivolumab + ipilimumab regimen; it too demonstrated a survival benefit over chemotherapy alone (HR ~0.69)drugs.com. Furthermore, in early-stage (resectable) NSCLC, the phase 3 CheckMate-816 trial found that neoadjuvant nivolumab + chemotherapy produced significantly higher pathological complete response rates (24% vs 2%) and longer event-free survival than chemotherapy alone, supporting its approval for neoadjuvant usedrugs.com. Collectively, these trials firmly established nivolumab’s efficacy in lung cancer, showing improved response rates, longer PFS/OS, and 3+ year survivors in scenarios where chemotherapy historically had poor long-term outcomesnews.bms.com.

Renal Cell Carcinoma: In metastatic RCC, nivolumab has shown marked efficacy both alone and in combinations. The phase 3 CheckMate-025 trial tested nivolumab monotherapy vs everolimus in patients who had failed prior anti-angiogenic therapy. Nivolumab improved median OS to 25.0 months, compared to 19.6 months with everolimus (HR 0.73) and nearly doubled the objective response rate (25% vs 5%)pmc.ncbi.nlm.nih.gov. This was the first immunotherapy to show OS benefit in RCC and led to nivolumab’s approval in the second-line setting. Subsequently, CheckMate-214 evaluated nivolumab + ipilimumab versus the standard TKI sunitinib in previously untreated advanced RCC. Among intermediate- and poor-risk patients, the nivolumab/ipilimumab combo achieved superior OS (median OS not reached vs 26.0 months, HR 0.63) and a higher ORR (42% vs 27%), including a complete response rate of 9% versus 1% with sunitinibcancertherapyadvisor.com. This combination produced durable remissions, and at 30-month follow-up about 18% of patients on nivolumab/ipilimumab were in complete response. These results shifted the first-line standard for many RCC patients to immunotherapy. More recently, CheckMate-9ER (sponsored with Exelixis) showed that nivolumab combined with cabozantinib (a VEGFR inhibitor) significantly improved PFS (median 16.6 vs 8.3 months) and OS (HR 0.60) compared to sunitinib, with ORR ~55%pahealthwellness.com. This provided an alternative first-line option, particularly in all IMDC risk groups. Across trials, nivolumab regimens have delivered prolonged survival in RCC, and ongoing studies are examining sequencing and biomarkers to optimize patient benefit.

Hodgkin Lymphoma: Nivolumab has remarkable activity in relapsed/refractory classical Hodgkin lymphoma, a disease characterized by frequent PD-1 ligand expression on Reed-Sternberg cells. The single-arm phase 2 CheckMate-205 trial in cHL (multiple cohorts) reported objective response rates of ~65–73% in patients who had failed prior transplant and brentuximab vedotintargetedonc.com. For example, in one cohort of heavily pretreated cHL, the ORR was 73% (with ~20% complete responses)targetedonc.com. Responses were often durable; the median progression-free survival was around 14–15 months, and 5-year follow-up showed many patients maintaining long-term remission (5-year OS was ~80% in the pooled analysis, reflecting the young population and availability of subsequent therapies)pubmed.ncbi.nlm.nih.gov. These unprecedented results in refractory Hodgkin lymphoma led to accelerated approval. Nivolumab’s success, along with a similar PD-1 agent pembrolizumab, has made PD-1 blockade a standard salvage therapy in cHL, dramatically improving outcomes in patients who have exhausted conventional chemo and transplant optionstargetedonc.com.

Head and Neck Cancer: In recurrent/metastatic HNSCC, nivolumab was the first immunotherapy to demonstrate a survival benefit. The phase 3 CheckMate-141 trial compared nivolumab to single-agent chemotherapy (investigator’s choice of methotrexate, docetaxel, or cetuximab) in patients with HNSCC progressing on platinum-based therapy. Nivolumab significantly improved overall survival: median OS was 7.5 months with nivolumab vs 5.1 months with standard therapydrugs.com. This corresponded to a 30% reduction in risk of death (HR 0.70)drugs.com. One-year survival rates improved from ~17% to 36% with nivolumabdrugs.comdrugs.com. Importantly, this benefit was observed regardless of tumor HPV status; however, patients with PD-L1 expression ≥1% derived greater benefit than those without. The trial was stopped early due to clear efficacy, and nivolumab became a new standard after platinum failuredrugs.com. Subsequently, pembrolizumab (a PD-1 inhibitor) showed efficacy in first-line HNSCC (Keynote-048), but nivolumab remains a key option in the second-line setting. The immunotherapy has improved survival outcomes in a disease where second-line chemotherapy responses are poor, and about 15% of nivolumab-treated patients achieve long-term disease control.

Urothelial Carcinoma: Nivolumab was approved in platinum-refractory bladder cancer based on a single-arm trial (CheckMate-275). In this phase 2 study of metastatic urothelial carcinoma after platinum, nivolumab achieved an objective response rate of 19.6% (95% CI 15.0–24.9)news.bms.com. Although the ORR (~20%) might seem modest, responses were durable in many cases: the median duration of response exceeded 6 months and many responses were ongoing at analysisnews.bms.com. Notably, responses were observed in both PD-L1–positive and PD-L1–negative tumors (confirmed ORR ~23.8% if PD-L1 ≥1% vs 16.1% if PD-L1 <1%)news.bms.com. These data led to accelerated approval. However, unlike pembrolizumab (which in a randomized trial improved OS vs chemotherapy in this setting), nivolumab’s approval was not based on a survival benefit. Later trials of nivolumab in bladder cancer have included the CheckMate-274 study, which showed that adjuvant nivolumab after cystectomy significantly prolongs disease-free survival in high-risk muscle-invasive urothelial carcinoma compared to placebo (leading to the 2021 adjuvant approval)drugs.com. In summary, nivolumab provides a salvage therapy option for advanced bladder cancer with durable responses in a subset, and it has proven effective in the peri-operative (adjuvant) setting to reduce recurrence.

Colorectal Cancer (MSI-H): Nivolumab’s activity in MSI-H/dMMR colorectal cancer has expanded treatment options for this subset. MSI-H tumors are highly immunogenic, and PD-1 blockade yields notable efficacy. In the CheckMate-142 phase 2 trial, nivolumab monotherapy in chemorefractory MSI-H CRC achieved an ORR of ~31% with many additional patients achieving disease stabilization; responses were durable in most cases (median duration not reached at analysis)pahealthwellness.com. When nivolumab was combined with ipilimumab in a cohort of the same trial, the ORR increased to ~55%, with ~3% complete responses and prolonged survival signals, albeit with added toxicity. Based on this, nivolumab ± ipilimumab received accelerated approval for pretreated MSI-H CRCpahealthwellness.com. More recently, the phase 3 CheckMate-8HW trial evaluated nivolumab + ipilimumab as first-line therapy in MSI-H metastatic CRC. It showed a dramatic improvement in progression-free survival versus standard chemotherapy. In first-line patients, the nivolumab/ipilimumab combo reduced the risk of progression or death by 79% compared to chemotherapy (HR 0.21, 95% CI 0.14–0.32, P<0.0001)drugs.com. This was accompanied by a higher response rate and a trend toward improved overall survival, leading to regulatory approval of the combo in treatment-naïve MSI-H CRCdrugs.com. This represents a paradigm shift, as immunotherapy is now preferred over chemotherapy for metastatic colorectal cancer with DNA mismatch repair deficiency, given the substantially better outcomes.

Hepatocellular Carcinoma: Nivolumab has been evaluated in advanced HCC, a setting traditionally dominated by TKIs. In the non-comparative CheckMate-040 study, nivolumab showed an ORR ~15–20% in sorafenib-exposed HCC patients, with some prolonged responders, prompting accelerated approval in second-line HCCdrugs.com. However, the confirmatory CheckMate-459 trial (nivolumab vs sorafenib in first-line HCC) narrowly missed its primary OS endpoint (median OS 16.4 vs 14.7 months, HR 0.85, p=0.075), leaving uncertainty about single-agent nivolumab’s benefit in HCC. The post-sorafenib monotherapy indication was subsequently withdrawn in the U.S. in 2021 due to lack of confirmed survival benefitdrugs.com. On the other hand, nivolumab in combination with ipilimumab has shown higher activity. In a cohort of CheckMate-040, nivolumab+ipilimumab produced an ORR of ~32% in second-line HCC, including some complete responses (this regimen holds an accelerated approval for sorafenib-experienced patients)pahealthwellness.com. Most recently, the phase 3 CheckMate-9DW trial tested first-line nivolumab + ipilimumab vs standard TKIs (sorafenib or lenvatinib). The combination demonstrated statistically significant improvements in outcomes: patients on nivolumab+ipilimumab had superior overall survival and response rates compared to those on TKI monotherapydrugs.com. While exact figures are pending full publication, this led to FDA approval of the combo in April 2025 for untreated advanced HCCdrugs.com. These results position dual checkpoint blockade as a new option in HCC, alongside another immunotherapy regimen (atezolizumab + bevacizumab) that had earlier become a standard. Nivolumab’s trajectory in HCC illustrates both the challenges of demonstrating benefit and the potential of combination immunotherapy to achieve meaningful survival gains in this difficult disease.

Esophageal/Gastric Cancers: CheckMate-577 was a milestone trial in earlier-stage disease, showing that one year of adjuvant nivolumab after esophagectomy (for patients with residual tumor after neoadjuvant chemoradiotherapy) significantly improved disease-free survival versus placebo (median DFS 22.4 vs 11.0 months, HR ~0.69) in esophageal or GEJ cancerdrugs.com. This led to approval of nivolumab in the adjuvant setting, marking the first immunotherapy in that curative-intent context. In advanced esophageal squamous cell carcinoma, the ATTRACTION-3 trial (conducted in Asia) established nivolumab in the second-line: as noted above, nivolumab improved median OS to 10.9 months vs 8.4 months with chemotherapy (HR 0.77, p=0.019)fda.gov, even though tumor shrinkage rates were similar and PFS was not improved. This survival benefit (and better tolerability) led to global approvals for nivolumab after first-line chemo in ESCC. In the first-line setting, the CheckMate-648 trial tested two nivolumab regimens in metastatic ESCC: (a) nivolumab + chemotherapy and (b) nivolumab + ipilimumab, each against chemotherapy alone. Both experimental arms achieved superior OS. For example, nivolumab plus chemo prolonged median OS to ~13.2 months vs 10.7 months with chemo in PD-L1 positive tumors (HR ~0.54), and also improved OS in the all-randomized populationesmo.orgfda.gov. Nivolumab + ipilimumab also improved OS in PD-L1–high ESCC (median ~14 vs 10.5 mo, HR ~0.64). Based on this, the FDA (in 2022) approved nivolumab with chemo for all advanced ESCC and nivolumab+ipilimumab for PD-L1–unselected ESCC, giving multiple first-line optionspahealthwellness.com. In gastric and GEJ adenocarcinoma, the CheckMate-649 trial demonstrated that adding nivolumab to first-line chemotherapy yields significant benefits. Among patients with PD-L1 combined positive score ≥5, nivolumab + chemo improved median OS to 14.4 months vs 11.1 months with chemo (HR 0.71, p<0.0001)pubmed.ncbi.nlm.nih.gov. A survival benefit was also seen in the overall population (HR ~0.80). This was the first positive immunotherapy phase 3 trial in gastric/GEJ cancer, and it led to global approvals of nivolumab + chemo in first-line HER2-negative gastric, GEJ, and esophageal adenocarcinomadrugs.com. In summary, across esophageal and gastric cancers, nivolumab-based therapies have improved outcomes in both early (postoperative) and advanced disease settings, particularly in tumors with high PD-L1 expression or MSI-H status.

Malignant Mesothelioma: The CheckMate-743 trial was a phase 3 study in unresectable malignant pleural mesothelioma, comparing first-line nivolumab + ipilimumab to platinum/pemetrexed chemotherapy. Nivolumab + ipilimumab significantly extended overall survival, with a median OS of 18.1 months vs 14.1 months for chemotherapy (HR 0.74, p=0.002)cancertherapyadvisor.com. The 2-year survival rate doubled from 27% with chemotherapy to 41% with the nivolumab/ipilimumab regimencancertherapyadvisor.com. The benefit was especially pronounced in the non-epithelioid mesothelioma subtype (median OS 18.1 vs 8.8 months)cancertherapyadvisor.com, a group with particularly poor prognosis on chemo. These results, published in The Lancet, led to FDA approval of dual immunotherapy in mesothelioma in 2020. Nivolumab (with ipilimumab) thus became the first regimen to improve OS over the chemotherapy standard in this cancercancertherapyadvisor.comcancertherapyadvisor.com. This has established a new standard of care, especially since mesothelioma has historically been refractory to most treatments.

Collectively, the CheckMate clinical trial program (and related studies) has demonstrated nivolumab’s efficacy across a spectrum of malignancies, with benefits ranging from higher response rates and prolonged remission to significant gains in overall survival. These trials cement nivolumab’s role as a multi-indication therapy that has improved outcomes in diseases as diverse as melanoma, lung cancer, RCC, Hodgkin lymphoma, head and neck cancer, and beyond.

Comparative Effectiveness

Nivolumab vs Other Immunotherapies: As a PD-1 inhibitor, nivolumab’s clinical activity is often comparable to that of pembrolizumab (another PD-1 antibody) in similar indications. No head-to-head trials have been completed, but real-world analyses and cross-trial comparisons suggest no major differences in efficacy between nivolumab and pembrolizumab in most settingsnature.com. For example, in metastatic melanoma, both drugs produced similar survival outcomes and durable remissions when each was compared to ipilimumab in separate trialstandfonline.com. In advanced NSCLC, retrospective studies have reported that first-line pembrolizumab and nivolumab (when used according to their approved criteria) yielded equivalent progression-free survival; one analysis found no significant PFS difference between patients treated with pembrolizumab vs nivolumab after adjusting for covariatesnature.com. Pembrolizumab showed a higher objective response rate in some series (especially in first-line use where pembrolizumab is given to PD-L1–high patients)nature.com, but overall survival outcomes were similar, supporting the practice of choosing either agent based on clinical context and drug availabilitynature.comnature.com. Thus, for indications like melanoma or PD-L1–positive NSCLC, nivolumab and pembrolizumab are often considered interchangeable options with broadly comparable effectivenessnature.com. One notable practical difference is that pembrolizumab is approved as first-line monotherapy in certain PD-L1–expressing tumors (e.g. NSCLC with PD-L1 ≥50%, head & neck cancer with PD-L1 CPS ≥1, MSI-H cancers) whereas nivolumab’s first-line use has usually been in combination regimens or specific nichespahealthwellness.compahealthwellness.com. Nonetheless, when used in similar patient populations, the two PD-1 inhibitors achieve analogous long-term survival rates.

Nivolumab has also been compared to PD-L1 inhibitors (atezolizumab, durvalumab, avelumab) indirectly. In NSCLC, both nivolumab and atezolizumab improved survival vs docetaxel in second-line trials, and there is no clear evidence one is superior to the other. In urothelial carcinoma, pembrolizumab had level 1 evidence of OS benefit (Keynote-045) whereas nivolumab’s approval was ORR-based; however, in practice both are active, and pembrolizumab is often preferred in second-line bladder cancer due to the randomized data. In first-line metastatic RCC, nivolumab+ipilimumab is often compared to pembrolizumab plus axitinib (an immunotherapy/TKI combination). Both regimens achieved significant OS benefits over sunitinib in phase 3 trials, though via different mechanisms: CheckMate-214’s nivolumab+ipilimumab yielded a 37% reduction in risk of death vs sunitinib in intermediate/poor-risk patients, while Keynote-426’s pembrolizumab+axitinib showed a similar or greater OS hazard ratio (~0.53) in an all-risk population. The pembro+axitinib combination produced a higher initial response rate (~59% vs ~42% with nivolumab+ipi), but nivolumab+ipilimumab produced more complete responses and some patients remain disease-free off therapy. Toxicity profiles differ (immune-related events for nivolumab+ipi, vs vascular and hepatic side effects for pembro+axi). No direct trial has compared these approaches, but both are regarded as valid standards, and the choice may depend on patient factors (e.g. tumor burden, risk category, comorbidities). Thus, in RCC the comparative effectiveness is context-dependent: nivolumab+ipi offers the benefit of a treatment-free interval after induction (for responders) and durable remission in a minority, whereas PD-1 + TKI therapy offers a high response rate and PFS advantage at the expense of continuous therapy.

In melanoma, nivolumab and pembrolizumab monotherapies have shown very similar 5-year survival (~44–45%) in advanced diseasenejm.org. Both outperform ipilimumab dramatically, roughly doubling OS rates compared to ipilimumab alonenejm.org. The combination of nivolumab+ipilimumab yields incrementally higher survival (52% at 5 years) at the cost of greater toxicitynejm.org. Pembrolizumab has not been combined with CTLA-4 blockade in clinical practice, but it has been combined with other agents (e.g. IDO inhibitors or LAG-3 inhibitors) in trials. Overall, nivolumab’s efficacy in melanoma is essentially on par with pembrolizumab’s, and both are clearly superior to the older immunotherapy (ipilimumab) in both metastatic and adjuvant settingspmc.ncbi.nlm.nih.gov.

In lung cancer, the landscape is nuanced. Pembrolizumab is established as first-line therapy for metastatic NSCLC with high PD-L1 expression (≥50%), whereas nivolumab pursued a combination strategy (nivolumab+ipilimumab) for PD-L1 ≥1% tumorspahealthwellness.com. Both strategies improved OS vs chemotherapy. Indirect comparisons suggest outcomes for PD-1 inhibitors are broadly similar when patients are appropriately selected. For example, in a retrospective study of PD-L1-positive, previously treated NSCLC, nivolumab and pembrolizumab had no significant difference in efficacy or safetysciencedirect.comlungcancerjournal.info. However, pembrolizumab has the advantage of monotherapy approval in first-line (which nivolumab lacks), meaning pembrolizumab might be used preferentially in a patient who could avoid chemotherapy. On the other hand, nivolumab’s combination with ipilimumab provides a chemo-sparing regimen for PD-L1 ≥1% patients (CheckMate-227) and an option for PD-L1 <1% when combined with limited chemotherapy (CheckMate-9LA). In practice, the choice may come down to PD-L1 level and physician comfort: for a high PD-L1 NSCLC, pembrolizumab monotherapy is simple and effective, whereas for PD-L1 low tumors, nivolumab+ipilimumab+chemo is one of several options (alongside chemo+pembrolizumab). Thus, the comparative effectiveness of nivolumab vs pembrolizumab in lung cancer is less about potency differences and more about label and regimen differences, with both drugs significantly extending survival in their niches.

Nivolumab vs Standard Non-Immunotherapy Treatments: Across cancers, nivolumab has generally been compared to prior standards (chemotherapy, targeted therapy) and has often demonstrated superior outcomes. For instance, in platinum-refractory head and neck cancer, nivolumab’s OS benefit over methotrexate/docetaxel (median 7.5 vs 5.1 months) established a new standarddrugs.com. In second-line NSCLC, nivolumab’s clear survival advantage over docetaxel (HR ~0.70) changed practice, replacing chemo in that settingnews.bms.com. In renal carcinoma, nivolumab showed improved survival and quality of life vs everolimuspmc.ncbi.nlm.nih.gov. Not all comparisons have been positive – for example, in first-line gastric cancer, nivolumab+ipilimumab (checkpoint-blockade only) was tested against chemo in a subset of CheckMate-649 but did not improve survival in all-comers (that dual-IO arm did not meet its endpoint in PD-L1 unselected patients)nature.com, underscoring that nivolumab works best either with chemo or in biomarker-selected groups in GI cancers. In first-line HCC, as noted, nivolumab monotherapy did not beat sorafenib in a phase 3 trial, whereas atezolizumab+bevacizumab did – highlighting that different immunotherapy approaches can yield different comparative results. However, nivolumab+ipilimumab has now demonstrated superiority to sorafenib/lenvatinib, giving another effective optiondrugs.com. In mesothelioma, nivolumab+ipi achieved an unprecedented survival gain vs chemotherapy (HR 0.74)cancertherapyadvisor.com.

Another aspect of comparative effectiveness is toxicity and patient experience. Nivolumab generally confers significant survival or response benefits over chemo while also offering a more favorable side effect profile in many cases (less acute toxicity such as nausea, cytopenias, etc., though introducing immune-mediated toxicities). For example, in CheckMate-141 for HNSCC, fewer patients on nivolumab experienced severe adverse events than on investigator’s choice chemodrugs.com. Similarly, in NSCLC trials, nivolumab was better tolerated than docetaxel (fewer grade 3–4 events). That said, immune-related adverse events (irAEs) can be serious (see Safety section below), so the trade-off is different rather than uniformly “easier.”

In summary, compared to other checkpoint inhibitors, nivolumab’s effectiveness is roughly equivalent, with selection often driven by indication-specific approvals (e.g., pembrolizumab for certain first-line uses, nivolumab for certain combos). Compared to traditional therapies (chemotherapy, targeted agents), nivolumab has frequently demonstrated improved efficacy and durability of response in populations that historically had limited options, thereby shifting treatment paradigms in multiple diseasesnews.bms.comdrugs.com. The ongoing refinement of biomarkers (PD-L1, TMB, etc.) and combination strategies will continue to define how nivolumab is best utilized relative to other treatments.

Safety Profile

Common Adverse Effects: Nivolumab is generally better tolerated than cytotoxic chemotherapy, but it does cause a range of immune-mediated and other side effects. Common side effects (any grade) reported in ≥10% of patients include fatigue, rash, pruritus (itching), diarrhea, nausea, decreased appetite, constipation, cough, dyspnea, musculoskeletal pain, upper respiratory infections, fever, and anemiafda.gov. Many of these are mild to moderate in severity. For example, cutaneous reactions like rash and itching are frequently observed but can often be managed with topical therapy or antihistamines. Gastrointestinal symptoms (mild diarrhea, nausea) occur in some patients, though severe diarrhea warrants investigation for colitis (see below). Fatigue is one of the most commonly reported complaints and can range from mild lethargy to more pronounced tiredness affecting daily activities. These side effects tend to be less severe than those from chemotherapy (no hair loss, no severe nausea/vomiting, less myelosuppression), which contributes to the favorable tolerability of PD-1 therapy.

Immune-Related Adverse Events (irAEs): The most important toxicities of nivolumab are immune-related adverse events caused by immune system activation against normal tissues. Because PD-1 blockade removes inhibitory checks, T-cells can attack healthy organs, leading to inflammatory side effects that can affect virtually any organ system. The well-recognized irAEs with nivolumab (as with other PD-1/PD-L1 and CTLA-4 inhibitors) include:

• Dermatologic: immune-mediated dermatitis and rash. This can range from mild maculopapular rashes to rare severe forms like Stevens-Johnson syndrome. Most rashes are low-grade and manageable with topical steroids; severe cases may require systemic corticosteroids.
• Gastrointestinal: colitis is a serious concern. Immune-mediated colitis typically presents with diarrhea, abdominal pain, and can progress to bloody stool with endoscopic evidence of colonic inflammation. Nivolumab-induced colitis usually responds to immunosuppressive therapy (high-dose corticosteroids, and infliximab or vedolizumab if refractory). Early intervention is key to prevent complications like perforation. Mild diarrhea without colitis is relatively common and must be distinguished from true colitis.
• Hepatic: hepatitis can occur, indicated by asymptomatic elevation of AST/ALT or, rarely, fulminant liver inflammation. Immune-mediated hepatitis is usually identified via lab tests. For grade 3–4 hepatitis (ALT or AST >5–10× upper limit), nivolumab is held and corticosteroids are initiated.
• Endocrine: endocrinopathies are among the most frequent irAEs. Hypothyroidism (or thyroiditis leading to hypothyroidism) occurs in a significant fraction of patients – many develop thyroid dysfunction requiring long-term thyroid hormone replacementfda.gov. Hyperthyroidism can also occur transiently (thyroiditis phase) before transitioning to hypo. Hypophysitis (inflammation of the pituitary) is less common with PD-1 inhibitors than with CTLA-4 inhibitors like ipilimumab, but cases have been reported with nivolumab. Hypophysitis can cause pituitary hormone deficiencies (ACTH, TSH, etc.), leading to headaches and fatigue; it typically requires hormone replacement (e.g., adrenal and thyroid) potentially lifelong. Primary adrenal insufficiency is rare but possible. Type 1 diabetes mellitus is a rare irAE resulting from autoimmune islet cell destruction – it presents as new-onset diabetes with ketoacidosis and requires insulin therapy permanently. Collectively, these endocrine irAEs often require chronic management, but they are manageable with proper identification (e.g., checking TSH, cortisol periodically during therapy).
• Pulmonary: pneumonitis (immune-mediated inflammation of the lung parenchyma) is a serious and potentially life-threatening irAE. Incidence is on the order of 2–5% in trials, but can be higher in lung cancer patients (who may have compromised lungs). Patients present with new cough, dyspnea, hypoxia, and imaging (CT scan) shows interstitial or pneumonitic infiltrates. High-grade pneumonitis necessitates prompt steroids; if severe, hospitalization and immunosuppressants (e.g., infliximab) may be required. Pneumonitis is a leading cause of PD-1 inhibitor–related fatality if not recognized.
• Renal: nephritis (immune-mediated nephritis/interstitial nephritis) is less common (<1%), but can cause acute kidney injury. Monitoring renal function is advised; significant creatinine rises prompt workup (e.g., biopsy) and typically steroid treatment.
• Neurologic: Although rare, immune-mediated neurologic events can occur, such as neuropathies, aseptic meningitis, encephalitis, or demyelinating syndromes (e.g., Guillain-Barré). The FDA label for nivolumab lists encephalitis as a potential immune-mediated adverse reactiondrugs.com. Any new neurologic symptoms (confusion, motor or sensory deficits) require evaluation to rule out autoimmune causes. High-dose steroids or other immunosuppressants are used for severe cases.
• Others: Less frequent irAEs include immune-mediated hematologic disorders (like hemolytic anemia, thrombocytopenia), cardiac events (myocarditis, pericarditis; myocarditis is rare but often fatal if it occurs, especially in combination therapy), ocular inflammation (uveitis), and immune-mediated pancreatitis. Any organ can be a target: e.g., immune-mediated colitis, pneumonitis, hepatitis, endocrinopathies, nephritis, and skin reactions are explicitly highlighted in prescribing informationdrugs.com.

The overall incidence of grade ≥3 (severe) immune-related adverse events with nivolumab monotherapy is in the range of ~10–20% (varies by trial and population). In combination with ipilimumab, toxicity rates are higher (grade ≥3 irAEs in ~55% of patients in melanoma trials). Most irAEs are reversible if identified early and treated with immunosuppressive therapy according to established guidelines (e.g., ASCO or NCCN toxicity management guidelines). Nivolumab should be permanently discontinued for certain severe irAEs (e.g., life-threatening pneumonitis, neurologic reactions, myocarditis), and rechallenge is generally avoided after severe events.

Safety Compared to Other Therapies: Nivolumab’s safety profile is considered favorable relative to chemotherapy in that it lacks many traditional toxicities (no marrow suppression, neuropathy, etc.), and patients often maintain a good quality of life on therapy. In long-term survivors, chronic low-grade toxicities like hypothyroidism are manageable. However, the possibility of sudden severe irAEs means patients require monitoring and education. Some immune toxicities can be irreversible (e.g., endocrine deficiencies). When comparing nivolumab to pembrolizumab, the spectrum of PD-1 class toxicities is similar; no clear difference in frequency of irAEs has emerged between the two. Compared to CTLA-4 inhibitor ipilimumab, nivolumab causes fewer severe irAEs – for example, colitis and hypophysitis are much more common with ipilimumab. This underlies why PD-1 inhibitors largely replaced CTLA-4 monotherapy in many diseases: they are both more effective and better toleratedpmc.ncbi.nlm.nih.gov.

In summary, nivolumab is generally well tolerated, with a side effect profile dominated by immune-mediated events. Common mild effects include fatigue and rash, while serious toxicities like pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and infusion reactions can occurdrugs.com. With vigilance and prompt management, most irAEs can be mitigated. The safety profile has been well-characterized over years of clinical use, and guidelines exist to assist clinicians in managing these unique toxicitiespmc.ncbi.nlm.nih.gov.

Cost and Accessibility

Nivolumab is a high-cost biologic therapy, reflecting the expense of drug development and manufacturing, as well as its significant clinical benefits. In the United States, the list price of nivolumab is on the order of several thousand dollars per infusion. For example, one common dosing regimen is 240 mg every 2 weeks (or 480 mg every 4 weeks); at U.S. list prices, this translates to well over $10,000 per month of treatment. Public data indicate that the annual cost of PD-1 inhibitor therapy is approximately $150,000–$200,000 per patient in the U.S. healthcare systemgoodrx.comgoodrx.com. (For context, pembrolizumab’s label price is about $11,300 per 3-week dose, or $22,700 per 6-week dose, totaling ~$191,000 per yeargoodrx.com. Nivolumab’s pricing is in a similar range, with some analyses citing roughly $9,300 per 28-day month at a dose of 3 mg/kg every 2 weeksncbi.nlm.nih.gov.) These figures are “list” prices; actual reimbursement rates may be lower due to insurance negotiations and rebates.

Insurance Coverage: In high-income countries, nivolumab is generally covered by health insurance or national healthcare systems for its approved indications, given its status as a standard-of-care therapy. In the U.S., Medicare and private insurers do cover nivolumab for FDA-approved uses, though patients may face high co-pays or co-insurance without supplemental plans. Manufacturer patient assistance programs exist to help eligible uninsured or underinsured patients, and there are also co-pay assistance foundations for expensive oncology drugsmedicalnewstoday.commedicalnewstoday.com. In Europe, coverage is typically provided through national health services after health technology assessment (HTA) processes. For instance, NICE in the UK has evaluated nivolumab in multiple indications. Pricing agreements (such as confidential discounts or outcomes-based schemes) are often made to ensure cost-effectiveness. Even so, some indications initially struggled to gain approval due to cost: e.g., NICE at first did not recommend nivolumab for some cancers until further price justification was provided, since base-case incremental cost-effectiveness ratios were above conventional thresholdsnice.org.uktandfonline.com. Over time, many of these issues have been resolved, and nivolumab is now broadly accessible in most high-income countries for approved uses, albeit with high expenditures by payers.

Global Pricing Variability: The cost of nivolumab can vary internationally. In countries with centralized price negotiations, the price per mg is often lower than U.S. list price. Middle- and upper-middle income countries may have access at a lower price through tiered pricing or biosimilar competition in the future. However, as of 2025, nivolumab remains under patent protection (no biosimilars available yet)medicalnewstoday.com, so lower-cost generic versions are not on the market. Some countries (e.g., India) have seen the emergence of compassionate use programs or special pharmacy-compounded versions at lower doses, but these are exceptions and not broadly available.

Cost-Effectiveness: Researchers have examined nivolumab’s value for money. Results vary by indication and health system willingness-to-pay threshold. In some settings, nivolumab has been deemed cost-effective (for example, second-line NSCLC in the U.S. was estimated to have an acceptable cost per quality-adjusted life-year gained given the survival benefit)europeanurology.comajmc.com. In others, especially for combinations, the cost per QALY is extremely high. For instance, analyses of nivolumab+ipilimumab in first-line RCC or nivolumab+chemo in gastric cancer have questioned cost-effectiveness unless substantial price discounts are appliedpmc.ncbi.nlm.nih.govsciencedirect.com. In practice, because immunotherapies can produce long-term remissions, traditional cost-effectiveness models may undervalue the “cure fraction” benefit. Nonetheless, the high drug costs pose challenges, and payers in many countries have required price reductions or risk-sharing arrangements to fund nivolumab. The Institute for Clinical and Economic Review (ICER) in the U.S. has included nivolumab in reports about oncology drug pricing, highlighting instances of annual price increases and the need for pricing aligned with benefitsicer.orgispor.org.

Accessibility in Low- and Middle-Income Countries: A significant concern is the limited access to nivolumab in low- and middle-income countries (LMICs). The drug’s high price and the need for infusion infrastructure mean that only a small fraction of patients in poorer regions receive it. It is estimated that <5% – and in many places only 1–3% – of eligible cancer patients in LMICs have access to modern immune checkpoint inhibitors like nivolumabannalsofoncology.org. In some LMICs, nivolumab is simply not marketed or is available only on a case-by-case import basis. Even where it is registered, the cost is often prohibitive for health systems and patients. For example, one analysis noted that standard-dose nivolumab (240 mg every 2 weeks) costs roughly $2,700 per dose in certain marketsannalsofoncology.org, a price far beyond the means of most patients and public hospitals in those countries.

To improve access, researchers and clinicians in some LMICs have explored alternative dosing strategies – e.g., “ultra-low-dose” nivolumab trials in India investigated whether lower-than-standard doses could still provide benefit at a fraction of the costascopubs.orgcancerworld.net. One such trial in head and neck cancer found some survival benefit using much lower doses of nivolumab combined with other therapiespmc.ncbi.nlm.nih.gov. While provocative, this is not yet practice-changing, and standard dosing remains the norm where it can be afforded. Some middle-income countries have negotiated price cuts or rely on donations. For instance, in certain cases BMS (the manufacturer) has patient assistance programs that offer free drug after a certain number of paid doses (the “buy X get Y free” model) to improve affordability. Nevertheless, the vast majority of patients in Africa, South Asia, and parts of Latin America who might benefit from nivolumab currently do not receive it, due to cost and resource constraints. Estimates from oncologists suggest that immunotherapy is currently available to only a tiny elite segment of patients in those regions (often via private sector or clinical trials), underscoring a major global equity gap in cancer careannalsofoncology.org.

Financial Toxicity: Even in wealthier countries, the high cost of nivolumab can cause financial strain for patients and healthcare systems. Patients without insurance coverage or with high co-pay requirements may face significant out-of-pocket costs, leading to financial toxicity (debt, reduced savings, etc.). On a system level, immunotherapies including nivolumab have been a driver of rising oncology drug expenditures. Many countries monitor budget impact; for example, the introduction of nivolumab and other similar drugs was associated with a sharp increase in cancer drug spending over the past decade. Payers have responded with utilization management strategies (like requiring prior authorizations or using clinical guidelines to ensure appropriate use).

In conclusion, while nivolumab has transformed outcomes in several cancers, its high price poses challenges. In well-resourced settings, it is covered but contributes to healthcare cost burdens and requires cost-effectiveness justification. In lower-resourced settings, access is very limited, with efforts underway to improve affordability. Global health initiatives and future availability of biosimilars may eventually broaden access, but as of 2025, nivolumab epitomizes the tension between cutting-edge efficacy and real-world affordability. Only 1–3% of patients in low-income regions who could benefit are receiving these drugsannalsofoncology.org, highlighting a need for international strategies to expand cancer immunotherapy access. Efforts such as price negotiations, dose optimization research, and inclusion of these agents in aid programs will be critical to ensure that the survival gains achieved with nivolumab can benefit patients worldwide, not just in wealthier healthcare systems.